<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01761110</url>
  </required_header>
  <id_info>
    <org_study_id>R34DA031066</org_study_id>
    <nct_id>NCT01761110</nct_id>
  </id_info>
  <brief_title>Pilot Test of a Community-based Buprenorphine Treatment Intervention</brief_title>
  <official_title>Development of a Community-based Buprenorphine Treatment Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine of Yeshiva University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The City University of New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington Heights Corner Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine of Yeshiva University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to pilot test the community-based buprenorphine treatment
      (CBBT) intervention, examining buprenorphine treatment initiation, opioid use, and HIV risk
      behaviors. Two groups of participants will be followed for 60 days, with 3 research visits.
      One group will be enrolled prior to the CBBT intervention (pre-intervention), and one group
      after the CBBT intervention (post-intervention). Data sources will include questionnaires,
      urine toxicology tests, and medical record data. We hypothesize that compared to the
      participants in the pre-intervention group, participants in the post-intervention group will
      be more likely to initiate buprenorphine treatment, reduce opioid use, and reduce high-risk
      HIV risk behaviors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>initiation of buprenorphine treatment</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Medical record information will be extracted to determine initiation of buprenorphine treatment, which will be defined as a visit with a medical provider in which buprenorphine is prescribed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>opioid use</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Opioid use will be determined via self-report using the Addiction Severity Index and via urine specimens (e.g., urine toxicology testing).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HIV risk behaviors</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Drug- and sex-related HIV risk behaviors will be assessed using a standardized risk assessment tool used in NIDA's Clinical Trials Network.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Injection Drug Use</condition>
  <arm_group>
    <arm_group_label>Pre-intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Community-based buprenorphine treatment (CBBT) intervention</intervention_name>
    <description>Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.</description>
    <arm_group_label>Post-intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years old

          -  English or Spanish fluency

          -  ever injected drugs

          -  not receiving buprenorphine treatment (no prescribed buprenorphine in the previous 6
             months)

          -  clients of our collaborating community-based organization

          -  interested in buprenorphine treatment

        Exclusion Criteria:

          -  pregnant

          -  taking more than 60mg of methadone daily in the previous 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chinazo Cunningham, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine of Yeshiva University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chinazo Cunningham, MD.MS</last_name>
    <phone>718-944-3860</phone>
    <email>ccunning@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mia Brisbane, MPH</last_name>
    <phone>718-944-3840</phone>
    <email>mbrisban@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington Heights Corner Project</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taeko Frost, MPH</last_name>
      <phone>212-923-7600</phone>
    </contact>
    <investigator>
      <last_name>Taeko Frost, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 2, 2013</lastchanged_date>
  <firstreceived_date>January 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid dependence</keyword>
  <keyword>Injection drug use</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Opioid agonist treatment</keyword>
  <keyword>Access to care</keyword>
  <keyword>HIV risk behaviors</keyword>
  <keyword>Opioids</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
